A director at Kinder Morgan Inc sold 50,000 shares at 19.750USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Two Directors at Weis Markets Inc bought 1,625 shares at between 64.980USD and 66.560USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio Welcomes clients and members to its best-in-class platform DRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio. HealthEquity Chief Executive Officer, Jon Kessler said, "We are thrilled to welcome BenefitWallet clients and members as partners on our mission to save and improve lives by em...
Kinder Morgan (KMI) is the biggest natural gas pipeline company in the U.S. Its dominant position has allowed it to have stable profitability the last several years even when natural gas prices and volumes were low. Now that the natural gas market is improving thanks to better compression technology and higher demand from Europe, Kinder Morgan can start making more money on its contracts. Uniform Accounting highlights that the market is not pricing in a profitability inflection for the company,...
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial resul...
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (the “Company”) today announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, 2024 (as amended, the “amended forbearance agreement”) to extend the forbearance period to June 4, 2024. The lenders have also agreed to defer the $10 million principal payment previously due at May 15, 2024 to June 17, 2024. Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, 2024, so lo...
HealthEquity Sets Date to Announce First Quarter Results Presentation at Conferences DRAPER, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its first quarter of fiscal 2025 financial results following the close of regular stock market trading hours on Monday, June 3, 2024. Following the news release, HealthEquity management plans to host a conference call for investors on Monday, June 3, 2024, at 4:30 p.m. Eastern Time during which m...
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright 2nd Annual BioCon...
Team Member Feedback Earns HealthEquity Workplace Culture Recognition For the fourth consecutive year, team members' feedback has propelled HealthEquity to be recognized for cultural excellence DRAPER, Utah, May 02, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY), the nation’s largest Health Savings Account (HSA) custodian has received a Culture Excellence Award by Top Workplaces for the fourth consecutive year. "Our teammates deserve all the credit when it comes to this award,” said Cheryl King, executive vice president and chief human resource officer. “They have embraced o...
American Assets Trust, Inc. Reports First Quarter 2024 Financial Results Net income available to common stockholders of $19.3 million for the first quarter, or $0.32 per diluted share. Funds from Operations ("FFO") per diluted share increased 8% year-over-year for the first quarter to $0.71 per diluted share. Increased 2024 FFO per diluted share guidance to a range of $2.24 to $2.34 with a midpoint of $2.29, a 1% increase over prior guidance. SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.